USPTO Patents Application 09993647

ElcwilUlllw nwlMlUWlcUMclllclll newel IJ 1

EFSID:

7718589

Application Number:

09993647

International Application Number:

Confirmation Number:

1010

Title of Invention:

omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors

First Named Inventor/Applicant Name:

Bernd Riedl

Customer Number:

23599

Filer:

Csaba Henter/Caitlin Sickler

Filer Authorized By:

Csaba Henter

Attorney Docket Number:

BAYER 18A

Receipt Date:

01-JUN-2010

Filing Date:

27-NOV-2001

Time Stamp:

14:03:43

Application Type:

Utility under 35 USC 111(a)

Payment information:

Submitted with Payment

no

File Listing:

Document
Number

Document Description

File Name

FileSize(Bytes)/
Message Digest

Multi
Part /.zip

Pages
(if appl.)

1

NPL Documents

P70a-Dunst-et-al-Strahlenther-
Onkol-v177-p469.pdf

118016

a3479c41 1 ebclbcl83db725c5ed320d1 3f3dt
4f4da

no

5

Warnings:

Information:

2

Information Disclosure Statement (IDS)
Filed (SB/08)

P71-EBOS-MultipleCirculation.
pdf

396525

no

6

a2fc5eee7fc02873c7eccf4823309289316d2
af7

Warnings:

Information:

This is not an USPTO supplied IDS tillable form

3

NPL Documents

P71 a-Ebrahimi-et-al-Cancer-
Vl01-n12-p2727.pdf

1750542

no

10

274073b4ab204821b58025b55eb8d94ea7
6721 bO

Warnings:

Information:

4

NPL Documents

P72-

EisenPhaselTrialofBAY43-9006S
orafenibCombinedwithDacarb
azineDTICinMetastaticMelano

66103

no

1

3a7f066aab69cb1 72c667761 be6e3477f0a3
857d

Warnings:

Information:

5

NPL Documents

P73-EISENETAL-
SorafenibAdvancedMelanoma.
pdf

1392300

no

14

f99cd649a550b3eef8d1533f5821ea8a169f
6448

Warnings:

Information:

6

NPL Documents

P74-

EisenhauerlmpactofNewNon-
CytotoxicsintheTreatmentofOv
arianCancer.pdf

560154

no

5

be9b50cb492a6951 6f1fb58fa5fb1 3e1 aea5
77e6

Warnings:

Information:

7

NPL Documents

p75.pdf

178921

no

10

905 b68e3e38f9a738d4e278ba77677210dO
391 a2

Warnings:

Information:

8

NPL Documents

P76EltingBiomarkersassociated
withclinicaloutcomes.pdf

57666

no

2

304c0e1 5483657ea1 07c07c1f7544df5f6da
a3b7

Warnings:

Information:

9

NPL Documents

P77-

EscudierRandomizedPhaselllTri
aloftheRafKinaseandVEGFRInhi
bitorSorafenib.pdf

71404

no

1

753890aeb5577b3cfc9c9bf5940b45db5d1
30347

Warnings:

Information:

10

NPL Documents

P78-ESCUDIERETAL-
SorafenibAdvancedClearCell.
pdf

1 1 54369

no

17

8e3544f0f0b046a16d67c3b5e6a0b44140e
b5155

Warnings:

Information:

11

NPL Documents

P79-

EUROPEANMEDICINESAGENCY.
pdf

4589363

no

63

2c39c7ca5a0ed51 7f3002da1 9e4e7669860c
1d56

Warnings:

Information:

12

NPL Documents

P79a-

FabianetalSmallMoleculeKinase
lnteractionMap.pdf

1259199

no

12

C8cdb79966977460eaeba3d0136f68245ca
2ab97

Warnings:

Information:

13

NPL Documents

P79b-Faderl-et-al-Blood-v1 5-
p4303.pdf

101979

no

5

2751f59b9b909f36f8af405ddb2730d049a6
76d4

Warnings:

Information:

14

NPL Documents

P80-FAIVRE-
MolecularBasisforSunitinibEffic
acy.pdf

1710238

no

12

94c5b43e5 8848c8fc88ac2cd3fabe7fc33f5a
f46

Warnings:

Information:

15

NPL Documents

P80a-Fakhari-et-al-J-Ped-Surg-
v-37-n4-p582.pdf

7114786

no

6

d61 89b331 5a6bf858f8cc3eac5b0dcf51 8a0
84f3

Warnings:

Information:

16

NPL Documents

P81-FAVARO-
TargetedTherapyinRenalCellCa
rcinoma.pdf

837301

no

8

b5814ae287dee8034d0f56c927255b64218
14b65

Warnings:

Information:

17

NPL Documents

P81a-Fiedler-et-al-Blood-v102-
n8-p2763.pdf

779982

no

5

70c96f825a36e6eb45ed9ed2e5cd2da85b8
31aef

Warnings:

Information:

18

NPL Documents

P82-Feldmann-
Naturelmmunology.pdf

289554

no

3

372a7e97320229392138134aadc4fb3df82
e18d5

Warnings:

Information:

19

NPL Documents

P83-FieldsVirology.pdf

313503

no

8

81b89ef6c0d6004ed6724ac31bbdf967c0fe
9a54

Warnings:
Information:

20

NPL Documents

P84-FLAHERTYETAL-
PhaselOralMultikinase.pdf

709902

9fecl8a0401e825c89369c820537f2fb2f969
44f8

Warnings:

Information:

Total Files Size (in bytes)

23451807

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents,
characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a
Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 1 1 1

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR
1 .53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1 .54) will be issued in due course and the date shown on this
Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35
U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a
national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for
an international filing date (see PCT Article 1 1 and MPEP 1 81 0), a Notification of the International Application Number
and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning
national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of
the application.